A trial fibrillation (AF) is associated with a ≈5-fold increased risk of ischemic stroke, 1 and stroke prevention is a major priority in the clinical management of AF. When compared with control/placebo, oral anticoagulation (OAC) therapy reduces the risk of stroke by 64% and the risk of death by 26%.
for ≥2 CHA 2 DS 2 -VASc stroke risk factors. [3] [4] [5] [6] However, these guideline recommendations were derived from the assumption that each score corresponds to fixed stroke rates, and most data for the CHA 2 DS 2 -VASc score were derived and validated in Western cohorts. 9, 10 Indeed, the application of CHA 2 DS 2 -VASc score to Asian populations has been debated because the annual stroke risk of some cohorts in Asian populations seems to vary from that reported from Western populations. [11] [12] [13] [14] [15] Ethnic differences may also be evident, with higher event rates in Chinese cohorts 15 compared with (for example) Japanese cohorts. 16 Using a nationwide cohort database, our objective was to investigate risk factors for stroke in AF and application of the CHA 2 DS 2 -VASc score in an Asian AF population from Korea.
Methods
National Health Insurance Service (NHIS) is the single insurer managed by the Korean government, and the majority of Korean population (97.1%) is mandatory subscribers, with the remaining 3% of the population being medical aid subjects. The database is open to researchers, whose study protocols are approved by the official review committee. Korean National Health Insurance ServiceSample Cohort (K-NHIS Sample Cohort) was created and released by NHIS in 2014 and contains 1 025 340 individuals representing the total Korean population from the beginning in 2002, amounting to 2.2% of the entire population in the Korean National Health Insurance Service, and followed by 2013. The database contains patients' sociodemographic information, their use of inpatient and outpatient services, pharmacy dispensing claims, and mortality data.
Study Population
A total of 7529 patients with AF who were aged ≥20 years were identified from Korea NHIS sample cohort database during the screening period from January 2002 to December 2008; 482 patients with valvular AF (mitral stenosis, any mechanical or bioprosthetic heart valve, or mitral valve repair) and 1192 patients receiving OACs at baseline were excluded. A final total of 5855 OAC-naive AF patients were enrolled in the study cohort and were followed up until December 2013 ( Figure 1 ). AF was identified with International Classification of Disease, Tenth Revision (ICD-10) codes; I48 (AF and atrial flutter), I48.0 (AF), and I48.1 (atrial flutter). To ensure accuracy, diagnosis was established based on 1 inpatient or 2 outpatient records of ICD-10 codes in the database. 17, 18 To evaluate the accuracy of our definition of AF, we conducted a validation study in two hospitals with 628 randomly chosen patients with the ICD-10 code I48. Their ECGs were reviewed by 2 physicians (Daehoon Kim and Junbeom Park). The patients were ascertained to have AF if it was documented by ECG examinations. The positive predictive value was found to be 94.1%.
Baseline Comorbidities and End Points
Baseline comorbidities were evaluated during the 7-year screening period (January 2002 to December 2008) and identified from the medical claims according to the ICD-10 codes and prescription codes, and all comorbidities were established based on 1 inpatient or 2 or more outpatient records of ICD-10 codes in the database, which was similar to previous studies with NHIS sample cohort. 19, 20 Hypertension, diabetes mellitus, chronic obstructive pulmonary disease, heart failure, end-stage renal disease, peripheral arterial disease, a history of myocardial infarction, and a history of stroke and transient ischemic attack were assessed. The CHA 2 DS 2 -VASc score for each subject was estimated at the end of the screening period. The use of aspirin was also assessed at the start of the follow-up period, and only prescriptions >3 months were counted. To avoid the underestimation of aspirin utilization because of over-the-counter purchase in the study population, we additionally analyzed the over-the-counter aspirin purchase data during the 5-year follow-up period. Definitions of comorbidities are presented in Table I in the online-only Data Supplement.
The primary end point was incident ischemic stroke (including ischemic stroke-related death) during the 5-year follow-up period (from January 2009 to December 2013). Any diagnosis of ischemic stroke with concomitant brain-imaging studies, including computed tomography or magnetic resonance imaging was defined as incident ischemic stroke. The secondary end point was the composite of primary end point and systemic embolism events (the composite thromboembolism end point), which was defined as having ICD-10 codes of atrial embolism (ICD-10: I74) or renal infarction (ICD-10: N280) as inpatient records. The accuracy of the diagnosis of an ischemic stroke in the NHIS claim data was previously validated.
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Statistical Analysis
Descriptive statistics were used to characterize baseline characteristics and comorbidities according to the CHA 2 DS 2 -VASc score. Continuous variables were expressed as the mean±SD, and categorical variables were reported as frequencies (percentage). The incidence rates of end points according to the CHA 2 DS 2 -VASc score are presented as 100 person-years and adjusted for exposure to aspirin treatment assuming that aspirin provides a 19% reduction in TE risk, 2 to give an indication 
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of untreated rate. To provide perspective, we also show event rates according to the CHA 2 DS 2 -VASc score in the non-AF population from this data set. The cumulative incidence of AF and differences according to the CHA 2 DS 2 -VASc score were displayed and estimated by the Kaplan-Meier analysis using the log-rank test. To explore determinants for the risk of stroke, Cox proportional-hazards regression analysis was used to investigate the association between the comorbidities and the incidence of ischemic stroke or the composite thromboembolism end point. Factors associated with outcome after age and sex adjustment were used in a conditional forward Cox regression analysis. The threshold for entry was 0.05 and for removal was 0.10. Remaining factors significantly associated with outcomes were retained for the final model. Interdependent covariables were not used simultaneously in any of the analyses. The patients were censored at the date when the ischemic stroke or the composite end point events occurred, at the date of their death, at the date of OAC initiation during follow-up period, or at end of follow-up.
To quantify the predictive value for ischemic stroke and the composite thromboembolism end point, we calculated the C statistics, which quantifies discriminant ability and is a measure of the area under the receiver-operator characteristic curve, and tested the hypothesis that these schemes performed significantly better than chance (indicated by a C statistic ≥0.5). The odds ratio for the increased relative risk of the absence of ischemic stroke was assessed by logistic regression analysis. All tests were 2-tailed, with P<0.05 considered significant. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS 23.0; SPSS, Inc, Chicago, IL).
Results
This study included 5855 OAC-naive nonvalvular AF patients (mean age: 43.9±11.5 years; female 48.4%) who had diagnosed AF during the 6-year screening period. Patients were classified according to CHA 2 DS 2 -VASc scores as low-risk (0 or 1 point [in female]), intermediate-risk (1 point in male), and high-risk (≥2 points) groups, respectively. Patients' distribution, demographic data, and comorbidities according to CHA 2 DS 2 -VASc scores are listed in Table 1 . The proportion of patients aged ≥75 years was 26.7% in total population. Hypertension was the most prevalent comorbidity (75.5%), followed by heart failure (31.9%), vascular disease (20.6%), and diabetes mellitus (19.9%). Baseline characteristics of 2 primary source cohort populations from which the CHA 2 DS 2 -VASc score was derived 9, 22 are also listed in Table 1 , for illustrative purposes.
Risk of Stroke
During the mean follow-up period of 50.6±17.6 months, 819 of 5855 patients (14.0%) experienced incident ischemic stroke. The incidence rates (per 100 person-years) of ischemic stroke or the composite thromboembolism end point show a clear increase with increasing CHA 2 DS 2 -VASc score (Table 2 ; Figure 2 ). The incidence rates (per 100 person-years) of ischemic stroke were 3.32 in the total study population, being 0.23 in low-risk, 1.04 in intermediate-risk, and 4.59 in highrisk patients. The incidence rates of ischemic stroke/systemic embolism of 2 primary source cohort populations according to CHA 2 DS 2 -VASc score are also listed in Table 2 , for illustrative purposes.
Patients who were categorized as low risk by the CHA 2 DS 2 -VASc score (ie, score 0 in males or 1 in females) consistently had an event rate <1% per year. The proportion of patients who remained in low risk gradually decreased from 14.7% at baseline to 11.4% at the end of follow-up (or within a year before stroke), and there were 6 thromboembolic events in these truly-low-risk patients during the entire follow-up period of 5 years (rate, 0.18 per 100 person-years; 95% confidence interval [CI], 0.14-0.25). A low-risk category in CHA 2 DS 2 -VASc score was predictive of the absence of ischemic stroke during the 5-year follow-up (odds ratio, 16.4; 95% CI, 8.8-30.8;
P<0.001).
Median CHA 2 DS 2 -VASc score in this cohort was 3.28 (± 2.08), and the predictive value of the CHA 2 DS 2 -VASc score for stroke was good, as reflected by C indexes for ischemic stroke at 1 year and 5 years of 0.719 (95% CI, 0.71-0.73; P<0.001) and 0.714 (95% CI, 0.70-0.73; P<0.001), respectively.
Comparison With the Non-AF Population
The overall risk of stroke and systemic embolism in OACnaive AF patients was increased ≈3-fold compared with ageand sex-matched non-AF subjects. Table II in the online-only Data Supplement provides details on event rates for each point of the CHA 2 DS 2 -VASc score, where AF patients had generally higher event rates compared with non-AF subjects. In the lowrisk group (ie, CHA 2 DS 2 -VASc 0 in males or 1 in females), the incidence per 100 person-years of stroke and systemic embolism was similar to that seen in the non-AF population (0.26 versus 0.23, respectively; Figure I in the online-only Data Supplement).
Risk Factors for Ischemic Stroke and the Composite Thromboembolism End Point
All risk factors, except female sex (hazard ratio [HR], 0.94; 95% CI, 0.82-1.07), included in the CHA 2 DS 2 -VASc-scoring system showed significant associations with incident ischemic stroke on univariate analysis (Table 3 ). These associations with ischemic stroke events were greatest for age ≥75 years (HR, 4.70; 95% CI, 3.32-4.37), history of stroke or transient ischemic attack (HR, 3.81; 95% CI, 3.32-4.37), end-stage renal disease (HR, 2.36; 95% CI, 1.56-3.57), and chronic obstructive pulmonary disease (HR, 1.72; 95% CI, 1.43-2.07).
On multivariable analysis, the significance of vascular disease (HR, 0.98; 95% CI, 0.84-1.15) or diabetes mellitus (95% CI, 1.13; 95% CI, 0.96-1.32) were attenuated after multivariate adjustment, and female sex (HR, 0.75; 95% CI, 0.63-0.86) had a lower risk of ischemic stroke than males. The risk factors with significant associations were virtually the same irrespective of whether the end point was ischemic stroke or composite thromboembolism event.
Discussion
In this nationwide study using a large real-world cohort of OAC-naive AF patients, we demonstrate that the CHA 2 DS 2 -VASc score shows good performance in the South Korean 
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population, particularly in defining the truly-low-risk AF patients for stroke. Almost all risk factors included in CHA 2 DS 2 -VASc-scoring system showed significant associations with ischemic stroke and the composite thromboembolism end point, although female sex was not an independent risk factor for ischemic stroke or the composite end point after multivariate adjustment.
Discrepancies in Reported Stroke Rates
Several studies have demonstrated that the net clinical benefit of OAC is evident in AF patients with one or more stroke risk factors. 23, 24 Various guidelines recommend OAC use based on the patients' risk of stroke by the CHA 2 DS 2 -VASc score. [3] [4] [5] [6] Unsurprisingly, there are variations in reported CHA 2 DS 2 -VASc point score stratum-specific stroke rates, reflecting different study settings, population cohorts, study methodology, or ethnic groups. 25, 26 Indeed, significant differences in reported event rates are evident in Asian studies, with higher event rates in Chinese cohorts. 16 One US study suggested that AfricanAmericans with AF merited one extra point for ethnicity on the CHA 2 DS 2 -VASc score, 27 whereas Chao et al 15 proposed a recalibration of the CHA 2 DS 2 -VASc score for Asians, with one point given for the age 50 to 64 years criteria.
Hence, additional studies are clearly needed to carefully define stroke rates in different ethnic groups. In this study, we have now demonstrated for the first time in a large Korean Asian population that there are comparable CHA 2 DS 2 -VASc point score stratum-specific stroke rates compared with that seen in several Western cohorts cited in guidelines. 22, 28 Also, AF patients had generally higher event rates for each point of the CHA 2 DS 2 -VASc score compared with non-AF subjects in our cohort. In the low-risk group (ie, CHA 2 DS 2 -VASc 0 in males or 1 in females), the incidence per 100 person-years of stroke and systemic embolism in AF patients was low and similar to rates seen in the non-AF population.
Defining the Truly-Low-Risk Patients
The suggested threshold of annual ischemic stroke risk for a favorable net clinical benefit from OAC for patients with AF is between 1% and 2%. 7 The introduction of non-vitamin K antagonist OACs with improved efficacy and safety compared with warfarin has lowered the threshold for OAC therapy for AF patients from an annual stroke rate of 1.7% with vitamin K antagonists to 0.9% with non-vitamin K antagonist OACs. 7 Indeed, the 1.7% per year annual risk treatment threshold with warfarin may even be lower with good-quality anticoagulation control, as reflected by a time in therapeutic range >70%. 29 Therefore, the focus has now shifted away from predicting high-risk patients toward identifying patients with a truly low risk of ischemic stroke in whom OAC has no net clinical benefit. 30 In this study, the incidence rates (per 100 person-years) of ischemic stroke were 0. 23 
Stroke Risk Factors
Several cohort studies have shown that female sex is a risk factor for stroke, albeit with an age dependency to this risk. [33] [34] [35] [36] [37] Several Asian cohort studies from Hong Kong, 11 China, 12 Taiwan, 38 and Japan 13 have suggested that female sex was not an independent risk factor for ischemic stroke, again suggesting some potential ethnic differences in the risk of stroke between Asian and non-Asian populations. Consistent with previous Asian studies, female sex was not a risk factor for stroke in our cohort and instead had a lower stroke risk of ischemic stroke than males. Beyond the biological difference between males and females, other sex differences in lifestyle patterns, social responsibility, and behaviors can make a different impact on the sex differences according to ethnicity. However, we are not able to identify these complicated factors within our cohort database. Further prospective studies are needed to evaluate this sex effect on stroke risk in AF patients. Other risk factors in our population such as older age, history of stroke or transient ischemic attack, heart failure, and hypertension remained independent stroke risk factors, consistent with Western cohorts.
Limitations
To our knowledge, this is the first population-based investigation in the Korean population to assess the risk of ischemic stroke in OAC-naive AF patients. Our study should be interpreted in the context of the following limitations. First, baseline AF diagnosis and estimation of incidence of ischemic stroke or systemic embolism were on diagnostic codes registered by the physicians; therefore, the diagnosis of AF and ischemic stroke could be inaccurate although the method for the diagnosis has been validated in previous studies, and our internal validation found a high correlation with actual AF diagnosis. Second, patients who received aspirin were enrolled in the present study; therefore, the stroke rate could be slightly affected by aspirin use, despite some adjustment for aspirin use in analyses.
Conclusions
The performance of CHA 2 DS 2 -VASc score in Asians is comparable with that seen in Western populations. The score shows good performance in defining the truly-low-risk AF patients for stroke/TE.
